Breaking News on Contract Research, Manufacturing & Clinical Trials

Report abuse about a comment

Sponsors involved as well

One should not forget that CROs still work for sponsors and do not conduct trials for themselves. The fact that sales outside the US have grown that much demonstrates that the big pharma , which is by far the biggest client of global CROs, is more and more interested in selling its products outside the US market. This is particularly true for emerging countries such as Brasil or India. And since it is way easier to get registration and to sell its drug, in Brasil for example, once trials have been conducted in the country, sponsors ask for CROs to have an international expansion. Therefore it is not only the CROs that are globalising, it is the whole pharma industry.

Posted by Guillaume Miara
30 August 2011 | 15h30

Please fill in the box below to tell us why you feel the post breaks our rules. When you are finished, click on "Send" so that it can be reviewed by a moderator.

Your name *
Your email *

We will not publish your email on the site

Reason *

Back to: Over 50% of sales at top CROs now made outside US; report

Spotlight

Biotech and pipeline refills add to preclinical turnaround, say analysts

Biotech and pipeline refills add to preclinical turnaround, say analysts

Demand from biotech firms and Big Pharma’s need to refill its pipeline is driving the preclinical services...

Drugmakers start your engines: GSK's Formula One discovery formula

Drugmakers start your engines: GSK's Formula One discovery formula

GSK has asked Formula One team Mclaren to help it discover drugs, arguing that Big Data expertise...

AmerisourceBergen to launch $100m distribution JV in Brazil

AmerisourceBergen to launch $100m distribution JV in Brazil

AmerisourceBergen (ABC) plans to buy a minority stake in a Brazilian drug wholesaler and outlined plans for...

AMRI to acquire CDMO Cedarburg for $41M

AMRI to acquire CDMO Cedarburg for $41M

AMRI will acquire Cedarburg Pharmaceuticals for $38.2m (€27.7) in cash, plus $2.8m of assumed liabilities, to expand...

Evotec buys academic asset management specialist

Evotec buys academic asset management specialist

Evotec AG has bought an asset management company that specialises in bringing academic discovery and development innovations...

Key Industry Events

Interphex 2014

New York, NY 10001 / Conference and exhibition

Read more

Access all events listing